Invent Medic’s receives notice of allowance for patent in the USA
Invent Medic has received notice of allowance for a patent application in the USA related to the company’s product Efemia bladder support. The patent will be valid until 2039.
The patent application (17/046,706) describes the current version of Efemia bladder support, including developments made of the product following the first patent (which is already approved in the USA) while delivering the same effect. Today’s announcement therefore constitutes an important strengthening of Efemia bladder support’s patent protection in one of the company’s most important markets.
“This strengthening of our patent protection for Efemia bladder support in the USA is positive for our ongoing process to establish the company in this market. Among other things, it contributes to a more favourable position when we proceed from talks to negotiations with potential business partners in the USA,” says Invent Medic’s CEO Karin Bryder.
When issuing a notice of allowance, the patent office has the intention to grant the patent application following the final steps of the procedure, such as payment of the patent fee.
For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.